Discover a study which explores the impact of MASLD on pregnancy, from preconception to postpartum. Learn more.

Researchers identified a rare variant on a single gene that appears to predispose patients to metabolic ...

hInstitute for Cardiometabolism and Nutrition, Sorbonne Université, Hôpital Pitié Salpêtrière, Paris, France ...

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay ...

Efimosfermin is a phase III-ready, potential best-in-class, investigational specialty medicine to treat and prevent progression of steatotic liver disease (SLD). Under the agreement, GSK will pay $1.2 ...

The tumor microenvironment (TME) is characterized by distinct metabolic adaptations that not only drive tumor progression but also profoundly influence immune responses. Among these adaptations, ...

PURPOSE: To determine the prevalence of non alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery and to identify risk ...

Karolinska Institutet. (2025, May 9). Fatty liver in pregnancy may increase risk of preterm birth. ScienceDaily. Retrieved May 26, 2025 from www.sciencedaily.com / releases / 2025 / 05 ...

and has been used to predict progression in patients with other liver-affecting diseases like hepatitis C. MASLD—formerly known as NAFLD, or non-alcoholic fatty liver disease—affects about 30% ...

Previous research has primarily targeted advanced OSCC, overlooking the early stages of tumor progression. The study uncovers the pivotal role of LSD1 in the progression of oral cancer.

A study co-led by Indiana University School of Medicine researchers presents a potential new strategy to prevent or slow the progression of Type 1 diabetes by targeting an inflammation-related ...